AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3308980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin in combination with trimethoprim-sulfamethoxazole
Number of subjects: 15
Study 29397146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received placemats featuring healthy 'Kids' Meals of the Day')
Number of subjects: 58
Study 29397146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no placemats)
Number of subjects: 58
Study 29397146 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who ordered a promoted healthy entrée
Number of subjects: 58
Study 27328486 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days followed by seven days of EE 10 mcg (21/7‐active)
Number of subjects: 246
Study 27328486 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days followed by no treatment (DSG/EE+no Tx)
Number of subjects: 246
Study 24953836 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 26
Study 24953836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22659624 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin 0.5 mg/kg intravenous bolus
Number of subjects: 36
Study 22659624 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin 0.75 mg/kg intravenous bolus
Number of subjects: 36
Study 22659624 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin 1.05 mg/kg intravenous bolus
Number of subjects: 36
Study 22659624 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg intravenous infusion per hour for 4 h
Number of subjects: 36
Study 22659624 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin
Number of subjects: 36
Study 20924150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar drink (100 mL containing 750 mg acetic acid)
Number of subjects: 30
Study 20924150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar capsules (9 capsules containing 750 mg acetic acid in total with 150 mL of water)
Number of subjects: 30
Study 20924150 — intervention group
Group type: COMPARATOR
Intervention: Reference (150 mL of water)
Number of subjects: 30
Study 20924150 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AUC(capsule-ref) and AUC(drink-ref)
Number of subjects: 30
Study 18410888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BIA) during hemodialysis sessions
Number of subjects: 7
Study 16190386 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pulmonary artery perfusion with oxygenated blood during CPB
Number of subjects: 30
Study 16190386 — intervention group
Group type: COMPARATOR
Intervention: Routine procedure of mitral valve replacement (Control)
Number of subjects: 30
Study 12028517 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic reason for participation
Number of subjects: 43
Study 12028517 — intervention group
Group type: COMPARATOR
Intervention: Self-rewarding reasons for participation
Number of subjects: 43
Study 10690113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional stress management program
Number of subjects: 0
Study 8700339 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg piroxicam cinnamate (Sinartrol)
Number of subjects: 60
Study 8700339 — intervention group
Group type: COMPARATOR
Intervention: 20 mg piroxicam cinnamate
Number of subjects: 60
Study 1833543 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml lignocaine, 0.5% (L)
Number of subjects: 41
Study 1833543 — intervention group
Group type: COMPARATOR
Intervention: 5 ml isotonic saline (S)
Number of subjects: 41
Study 6227296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (ASA/DPM)
Number of subjects: 47
Study 6227296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30920059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd‐YAG 1064 nm laser treatment
Number of subjects: 64
Study 30920059 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 64
Study 28283863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 60
Study 26942475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anterior‐inferior rotator interval portal (AI)
Number of subjects: 10
Study 26942475 — intervention group
Group type: COMPARATOR
Intervention: Trans‐subscapularis portal
Number of subjects: 10
Study 26942475 — intervention group
Group type: COMPARATOR
Intervention: Mean pullout strength at the 5:30 position (trans‐subscapularis)
Number of subjects: 10
Study 26942475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pullout strength at the 5:30 position (AI)
Number of subjects: 10
Study 25500129 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage tailored intervention (feedback letters tailored to motivational stage)
Number of subjects: 629
Study 25500129 — intervention group
Group type: COMPARATOR
Intervention: Minimal assessment only (control group)
Number of subjects: 629
Study 23132800 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin)
Number of subjects: 36
Study 23132800 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (20 mg lutein and 2 mg zeaxanthin)
Number of subjects: 36
Study 23132800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 36
Study 20075646 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25‐50 mg/d)
Number of subjects: 48
Study 20075646 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (0.5‐2 mg/d)
Number of subjects: 48
Study 18480522 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA using fentanyl and bupivacaine
Number of subjects: 30
Study 18480522 — intervention group
Group type: COMPARATOR
Intervention: IVPCA using morphine
Number of subjects: 30
Study 16163151 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt pins pressure during intramuscular injections
Number of subjects: 212
Study 16163151 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt pins pressure during subcutaneous injections
Number of subjects: 212
Study 16163151 — intervention group
Group type: COMPARATOR
Intervention: Placebo device during intramuscular injections
Number of subjects: 212
Study 16163151 — intervention group
Group type: COMPARATOR
Intervention: Placebo device during subcutaneous injections
Number of subjects: 212
Study 12051399 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 90
Study 12051399 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg/day
Number of subjects: 90
Study 12051399 — intervention group
Group type: COMPARATOR
Intervention: Amtolmetin guacyl (AMG) 1,200 mg over the first 3 days and 600 mg/day thereafter
Number of subjects: 90
Study 10029968 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Laser Flowmeter Model 21; tested under conditions with teeth in situ and extracted, or with pulp present and removed.
Number of subjects: 0
Study 10029968 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Laser Flowmeter Model 21; tested with teeth in situ.
Number of subjects: 0
Study 10029968 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Laser Flowmeter Model 21; tested on lingual and labial surfaces of teeth.
Number of subjects: 0
Study 7733183 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS-90 group (90 mg/kg of body weight/day)
Number of subjects: 18
Study 7733183 — intervention group
Group type: COMPARATOR
Intervention: FOS-120 group (120 mg/kg of body weight/day)
Number of subjects: 18
Study 1706023 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic blood pressure measurement device (A)
Number of subjects: 440
Study 1706023 — intervention group
Group type: COMPARATOR
Intervention: Auscultatory-mercury manometer (M)
Number of subjects: 440
Study 6621617 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY h 4502 (bifonazole) 1% cream/lotion applied once daily for 14 days
Number of subjects: 60
Study 6621617 — intervention group
Group type: COMPARATOR
Intervention: 2% miconazole cream applied twice daily
Number of subjects: 60
Study 31556937 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of dark chocolate containing 400 mg of flavanols
Number of subjects: 22
Study 31556937 — intervention group
Group type: COMPARATOR
Intervention: 7.5 g of milk chocolate
Number of subjects: 22
Study 30024861 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster vaccine (HZ/su)
Number of subjects: 0
Study 30024861 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated zoster vaccine (ZV)
Number of subjects: 0
Study 30024861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study 27836009 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200-1000 μg)
Number of subjects: 0
Study 27836009 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24048909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Group (AEG), n = 64, performing 24 weeks of aquatic exercises
Number of subjects: 108
Study 24048909 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG), n = 44, sedentary
Number of subjects: 108
Study 24048909 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 108
Study 24048909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Group (AEG)
Number of subjects: 108
Study 22451440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified exercises (e.g. rubber band resistance) for 12 weeks
Number of subjects: 46
Study 22451440 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation exercises without external resistance for 12 weeks
Number of subjects: 46
Study 20158297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 50 mg
Number of subjects: 44
Study 20158297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 100 mg
Number of subjects: 44
Study 20158297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 44
Study 20418768 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole needling
Number of subjects: 47
Study 20418768 — intervention group
Group type: COMPARATOR
Intervention: Traditional rope-ladder needling
Number of subjects: 47
Study 15757769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flucloxacillin on induction followed by an oral placebo (Group A)
Number of subjects: 157
Study 15757769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flucloxacillin on induction followed by an oral flucloxacillin course (Group B)
Number of subjects: 157
Study 15757769 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (Group C)
Number of subjects: 157
Study 12130606 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based exercise
Number of subjects: 1090
Study 12130606 — intervention group
Group type: EXPERIMENTAL
Intervention: All three interventions combined (group based exercise, home hazard management, vision improvement)
Number of subjects: 1090
Study 12130606 — intervention group
Group type: COMPARATOR
Intervention: Home hazard management
Number of subjects: 1090
Study 12130606 — intervention group
Group type: COMPARATOR
Intervention: Vision improvement
Number of subjects: 1090
Study 10181572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive services performed by pharmacists
Number of subjects: 0
Study 10181572 — intervention group
Group type: COMPARATOR
Intervention: Financial incentives for pharmacists
Number of subjects: 0
Study 7846339 — intervention group
Group type: EXPERIMENTAL
Intervention: Air filtration units (AFUs) with high efficiency particulate air filter
Number of subjects: 12
Study 3072661 — intervention group
Group type: EXPERIMENTAL
Intervention: Silimarina (Legalon)
Number of subjects: 180
Study 29191873 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (intervention group)
Number of subjects: 59
Study 29191873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endovascular therapy)
Number of subjects: 59
Study 27924798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate-rich mineral water (1 l/day for 6 weeks)
Number of subjects: 100
Study 27924798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate-rich mineral water (1 l/day for 3 weeks)
Number of subjects: 100
Study 27924798 — intervention group
Group type: COMPARATOR
Intervention: Carbonated tap water (placebo, 1 l/day for 6 weeks)
Number of subjects: 100
Study 23897022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training (HSPT) at 40% of 1RM
Number of subjects: 72
Study 23897022 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional slow-speed strength training (SSST) at 80% of 1RM
Number of subjects: 72
Study 23897022 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 72
Study 22118842 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentectomy added to laparoscopic Roux-en-Y gastric bypass
Number of subjects: 28
Study 22118842 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass alone
Number of subjects: 28
Study 19897341 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 280
Study 19897341 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 280
Study 17965836 — intervention group
Group type: EXPERIMENTAL
Intervention: CoaguChek S
Number of subjects: 16
Study 17965836 — intervention group
Group type: COMPARATOR
Intervention: INRatio
Number of subjects: 16
Study 17965836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 16
Study 15983143 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental concentrations of sevoflurane (1% to 8%)
Number of subjects: 131
Study 15983143 — intervention group
Group type: EXPERIMENTAL
Intervention: Decremental-incremental concentrations of sevoflurane (8% to 4% to 8%)
Number of subjects: 131
Study 15983143 — intervention group
Group type: COMPARATOR
Intervention: Fixed concentration of sevoflurane (8%)
Number of subjects: 131
Study 12918553 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrapped hydroxyapatite implant
Number of subjects: 15
Study 12918553 — intervention group
Group type: COMPARATOR
Intervention: Unwrapped hydroxyapatite implant
Number of subjects: 15
Study 10945031 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 10945031 — intervention group
Group type: COMPARATOR
Intervention: LV.5-FU
Number of subjects: 0
Study 10945031 — intervention group
Group type: COMPARATOR
Intervention: CMF combination therapy
Number of subjects: 0
Study 8559367 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent brain infarcts
Number of subjects: 985
Study 1893683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Vacusac)
Number of subjects: 22
Study 1893683 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 1893683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Vacusac) after placebo
Number of subjects: 22
Study 6829673 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty treating 180 degrees of trabecular meshwork
Number of subjects: 40
Study 6829673 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty treating 360 degrees of trabecular meshwork
Number of subjects: 40
Study 31815678 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hypertension management messages
Number of subjects: 373
Study 31815678 — intervention group
Group type: COMPARATOR
Intervention: Passive health behavior messages
Number of subjects: 373
Study 29864132 — intervention group
Group type: EXPERIMENTAL
Intervention: FECPAKG2
Number of subjects: 615
Study 29864132 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz methods
Number of subjects: 615
Study 26597731 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance goals group (n=23)
Number of subjects: 48
Study 26597731 — intervention group
Group type: COMPARATOR
Intervention: Learning goals group (n=25)
Number of subjects: 48
Study 26597731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 24599532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide typhoid vaccine (25 μg, single dose)
Number of subjects: 120
Study 24599532 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 120
Study 21917503 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline rinsing of one eye after wearing PureVision™ lenses pre-soaked in ReNu MultiPlus® solution for 1 hour
Number of subjects: 13
Study 21917503 — intervention group
Group type: COMPARATOR
Intervention: No rinsing (control)
Number of subjects: 13
Study 20107304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 0
Study 20107304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 0
Study 17664472 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 92
Study 17664472 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 92
Study 16085692 — intervention group
Group type: EXPERIMENTAL
Intervention: PS‐341 1.5 mg/m(2) i.v. bolus on days 1, 4, 8 and 11 (Arm A)
Number of subjects: 81
Study 16085692 — intervention group
Group type: EXPERIMENTAL
Intervention: PS‐341 1.0 mg/m(2) plus gemcitabine 1,000 mg/m(2) i.v. on days 1 and 8 (Arm B)
Number of subjects: 81
Study 12489601 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0
Study 9833567 — intervention group
Group type: EXPERIMENTAL
Intervention: Crime committed in an unusual manner
Number of subjects: 371
Study 9833567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosecution motive information (strong, reasonable motive)
Number of subjects: 371
Study 9833567 — intervention group
Group type: EXPERIMENTAL
Intervention: Defense motive information (crazy, unreasonable motive)
Number of subjects: 371
Study 7865648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 12
Study 7865648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2518858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 10
Study 2518858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1065757 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised daily toothbrushing and flossing (10 sessions of instruction in plaque removal)
Number of subjects: 481
Study 1065757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction in oral hygiene procedures)
Number of subjects: 481
Study 1065757 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised daily toothbrushing and flossing
Number of subjects: 481
Study 31093987 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling based on the choice theory
Number of subjects: 50
Study 31093987 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 50
Study 31738351 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt group (consumed 112 mL yogurt drink fermented with OLL1073R‐1 daily for 16 weeks)
Number of subjects: 961
Study 31738351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yogurt consumption during the trial)
Number of subjects: 961
Study 31738351 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt group
Number of subjects: 961
Study 31738351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 961
Study 28565995 — intervention group
Group type: EXPERIMENTAL
Intervention: Free, healthy school meal served every school day for 6 months
Number of subjects: 164
Study 28565995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no free school meal)
Number of subjects: 164
Study 28565995 — intervention group
Group type: EXPERIMENTAL
Intervention: Free, healthy school meal
Number of subjects: 164
Study 25841077 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 0
Study 25841077 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study 23810041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Hawley/lower bonded
Number of subjects: 90
Study 23810041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Essix/lower bonded
Number of subjects: 90
Study 23810041 — intervention group
Group type: COMPARATOR
Intervention: Extraction treatment
Number of subjects: 90
Study 23810041 — intervention group
Group type: COMPARATOR
Intervention: Nonextraction treatment
Number of subjects: 90
Study 23810041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low discrepancy index scores group
Number of subjects: 90
Study 23810041 — intervention group
Group type: COMPARATOR
Intervention: High discrepancy index scores group
Number of subjects: 90
Study 21342748 — intervention group
Group type: EXPERIMENTAL
Intervention: Feed supplement
Number of subjects: 0
Study 21342748 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic chromium
Number of subjects: 0
Study 21342748 — intervention group
Group type: COMPARATOR
Intervention: Suffolk×Dorper (SD) genotype
Number of subjects: 0
Study 19763999 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus fructose + endurance exercise
Number of subjects: 20
Study 19763999 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus fructose + strength exercise
Number of subjects: 20
Study 19763999 — intervention group
Group type: COMPARATOR
Intervention: Glucose + endurance exercise
Number of subjects: 20
Study 19763999 — intervention group
Group type: COMPARATOR
Intervention: Glucose + strength exercise
Number of subjects: 20
Study 17173225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (2 g 3 times daily for 10 days)
Number of subjects: 14
Study 17173225 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (control group)
Number of subjects: 14
Study 15028553 — intervention group
Group type: EXPERIMENTAL
Intervention: S.S.GRIN (Social Skills GRoup INtervention)
Number of subjects: 381
Study 15028553 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (C)
Number of subjects: 381
Study 27841153 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of morniflumate 350-mg tablets
Number of subjects: 38
Study 27841153 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of morniflumate 350-mg tablets
Number of subjects: 38